Skip to main content
. 2016 May 4;7(24):36767–36782. doi: 10.18632/oncotarget.9168

Figure 6. Sorafenib treatment downregulates the PI3K/Akt/TOR signaling pathway in HLE cells and concomitant treatment with DCP attenuates this effect.

Figure 6

Western blot analysis was used to evaluate the expression of PI3K p110α, Akt, PDK, c-Raf and mTOR in HLE cells exposed to Sorafenib A. DCP B. and Sorafenib in the presence of DCP C. Gels were run under the same experimental conditions. The cropping lines in the figure represent full-length gels. Levels of proteins were compared to the vehicle control, which was set to 100%. Bars indicate means ± S.D. (n = 3). *p < 0.05, **p < 0.01 vs. the vehicle control.